Survival analysis, immune infiltration, pathway enrichment, and drug sensitivity were evaluated to validate the model.<h4>Results</h4>The ICDRS, based on eight key genes (IL32, AHNAK, ANXA5, FN1, GSN, CNN3, FXYD3, CTSS), effectively stratified BLCA patients into high- and low-risk groups with significant differences in overall survival (OS, P < 0.001). This evidence concerns the gene GSN and bladder transitional cell carcinoma.